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Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by com-
plex biological features and poor prognosis. A prognostic stratification of PDAC would help to improve
patient management. The aim of this study was to analyse the expression of Ki-67 in relation to prognosis
in a cohort of patients with PDAC who had surgical treatment.
Methods: Patients who had pancreatic resection between August 2010 and October 2014 for PDAC
at two Italian centres were reviewed retrospectively. Patients with metastatic or locally advanced dis-
ease, those who received neoadjuvant chemotherapy, patients with PDAC arising from intraductal
papillary mucinous neoplasm and those with missing data were excluded. Clinical and pathologi-
cal data were retrieved and analysed. Ki-67 expression was evaluated using immunohistochemistry
and patients were stratified into three subgroups. Survival analyses were performed for disease-free (DFS)
and disease-specific (DSS) survival outcomes according to Ki-67 expression and tumour grading.
Results: A total of 170 patients met the selection criteria. Ki-67 expression of 10 per cent or less, 11–50
per cent and more than 50 per cent significantly correlated with DFS and DSS outcomes (P = 0⋅016 and
P = 0⋅002 respectively). Ki-67 index was an independent predictor of poor DFS (hazard ratio (HR) 0⋅52,
95 per cent c.i. 0⋅29 to 0⋅91; P = 0⋅022) and DSS (HR 0⋅53, 0⋅31 to 0⋅91; P =0⋅022). Moreover, Ki-67 index
correlated strongly with tumour grade (P <0⋅001). Patients with PDAC classified as a G3 tumour with a
Ki-67 index above 50 per cent had poor survival outcomes compared with other patients (P < 0⋅001 for
both DFS and DSS).
Conclusion: Ki-67 index could be of use in predicting the survival of patients with PDAC. Further
investigation in larger cohorts is needed to validate these results.
Presented as a poster to Pancreas 2018, Baltimore, Maryland, USA, April 2018, and to the European Pancreatic Club,
Berlin, Germany, June 2018; published in abstract form as Pancreatology 2018; 18: S84
Funding information
No funding
Paper accepted 26 March 2019
Published online 10 May 2019 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.50175
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive
disease characterized by complex biological features and a
poor prognosis1,2. Recent literature3–5 in this field has
focused on molecular biomarkers and targets to improve
staging, treatment and, consequently, patient survival.
The expression of Ki-67 in tumour tissue is a well
known marker associated with tumour proliferation
and correlated with the progression, risk of metasta-
sis and prognosis of several tumours, including breast
and prostate cancers6–10. In pancreatic neuroendocrine
neoplasms (PanNENs), Ki-67 has been documented to
play an essential role in defining tumour grading and clas-
sification (WHO 2017/ENETS criteria), and is recognized
as an independent predictor of survival11–16. Moreover,
some authors17–20 have reported that the Ki-67 index
could be determined from selected PanNEN samples
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obtained by endoscopic ultrasonography–fine-needle
aspiration (EUS–FNA), thereby demonstrating its value
in the preoperative phase. In PDAC, the prognostic value
of Ki-67 has not yet been established21–23. The aim of
this study was to analyse the expression of Ki-67 as a
prognostic factor in a cohort of patients with resected
PDAC, in relation to survival outcomes.
Methods
This study was designed according to the REMARK24 and
STROBE25 guidelines. It was not preregistered with an
analysis plan in an independent institutional registry.
Patients who had a pancreatic resection for histologically
confirmed PDAC between August 2010 and October 2014
at the Ospedale Sacro Cuore – Don Calabria (Negrar,
Verona, Italy), a teaching hospital affiliated to the Univer-
sity of Verona, and at the Ospedali Riuniti Ancona Univer-
sità Politecnica delle Marche (Ancona, Italy), a university
hospital and referral centre for hepatobiliopancreatic
surgery in the Marche Region, were reviewed retrospec-
tively. Surgical resections were performed in both centres
by the same surgeons. Both institutions were documented
as high-volume centres for pancreatic surgery (more than
100 pancreatic resections annually) at the time of the study.
Patients with metastatic or locally advanced disease, those
who had received neoadjuvant chemotherapy, patients with
PDAC arising from intraductal papillary mucinous neo-
plasms, and patients with missing data or follow-up were
excluded. Written informed consent for use of their per-
sonal data and tissue for research purposes was obtained
from all patients included in the study. Institutional review
board approval was not required owing to the retrospective
nature of the study.
Data on patient demographics, clinical presentation,
tumour marker levels (serum carbohydrate antigen (CA)
19-9 and carcinoembryonic antigen (CEA)), preopera-
tive treatments, surgical and postoperative data, includ-
ing delivery of adjuvant treatment, were recorded. In the
absence of jaundice, the preoperative concentration of
CA19-9 was recorded; in patients with abnormal serum
bilirubin values at the time of diagnosis, the CA19-9 level
was determined after biliary drainage and jaundice reso-
lution. Pathology data included tumour size and grade,
number of resected/positive lymph nodes, TNM staging,
lymphatic and vascular invasion, perineural invasion and
margin status. Glandular differentiation and mitotic activ-
ity were evaluated in the entire tumour specimen and
the more severe grades were recorded. TNM staging was
done in accordance with the 7th AJCC system26, and
margin status was determined according to the 2010 WHO
definition27.
Table 1 Details of patients who had upfront surgery
No. of patients*
(n=170)
Age (years)† 70 (44–85)
Sex ratio (M : F) 92 : 78
Preoperative tumour marker levels†
CEA (ng/ml) 2 (0–90)
CA19-9 (units/ml) 36 (0–2689)
Jaundice at diagnosis 113 (66⋅5)
Duration of surgery (min)† 343 (120–575)
Postoperative complications 86 (50⋅6)
Pancreatic fistula 46 (27⋅1)
Biliary fistula 12 (7⋅1)
Duration of hospital stay (days)† 11 (5–70)
Readmission 50 (29⋅4)




















Lymphatic invasion 126 (74⋅1)
Vascular invasion 115 (67⋅6)






Adjuvant treatment 166 (97⋅6)
Recurrence 135 (79⋅4)
Died
Yes, from other cause 6 (3⋅5)
Yes, from pancreatic cancer progression 109 (64⋅1)
*With percentages in parentheses unless indicated otherwise; †values are
median (range). CEA, carcinoembryonic antigen; CA, carbohydrate anti-
gen.
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Fig. 1 Kaplan–Meier analysis of survival in Ki-67 index subgroups. a Disease-free (DFS) and b disease-specific (DSS) survival in
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Formalin-fixed specimens were processed into
paraffin according to standard practice. Sections
(5 μm) were stained with haematoxylin and eosin
for conventional histological examination, and used
for Ki-67 immunohistochemical analysis. For Ki-67
immunohistochemical staining, after deparaffinization
in xylene for 30–40 min, the specimen slides were rehy-
drated in a descending alcohol series, from absolute
ethanol to distilled water. Before staining, in order
to retrieve antigen epitopes, the samples were heated
in an aqueous sodium citrate solution in a microwave oven
(temperature 98∘C, pH 6) for 20 min. After microwave
treatment, the sections were cooled down for a fur-
ther 20 min. Endogenous peroxidase was blocked by 0⋅3
per cent hydrogen peroxide for 7 min. After washing
in Tris-buffered saline (TBS), the slides were incubated
at room temperature for 30 min with the primary anti-
body for Ki-67. The primary antibody was a monoclonal
mouse antihuman Ki-67 antigen (MIB-1; Dako, Glostrup,
Denmark) used at a dilution of 1 : 80. After incubation,
the primary antibody was washed away with TBS. The
slides were then incubated at room temperature for 20 min,
using the visualization system EnVision™ FLEX/HRP
(Dako) containing the secondary antimouse/rabbit anti-
body. Final staining was done with diaminobenzidine
tetrahydrochloride (DAB) solution for 10 min at room
temperature. Slides were then transferred through an
ascending ethanol series, finally through xylene, and then
mounted.
Two tissue blocks for each patient were selected from
the most representative area of the tumour (the region of
the tumour with highest grade). A section of each block
was immunolabelled for Ki-67 using the above protocol.
Counting of tumour cells was done manually using a Nikon
Eclipse 80i microscope (Nikon Instruments, Amsterdam,
the Netherlands), at 40× magnification. A counting pro-
tocol of 1000 cells was chosen to overcome the marked
cellular heterogeneity for each carcinoma, as the number
of high-power fields could be variable. The percentage of
Ki-67-positive cells was determined by scoring a minimum
of 1000 cells within a hotspot area (defined as the area in
which the 1000-cell count provided the highest percentage
of Ki-67-positive nuclei). Of note, the Ki-67 index was
counted in hotspot areas that did not necessarily parallel
the histological grade field by field.
Outcome measure
Primary outcome measures were disease-free survival
(DFS), the first recurrence of cancer after surgery,
and disease-specific survival (DSS), death from the disease.
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Table 2 Univariable and multivariable analyses of predictors of disease-free survival
Univariable analysis Multivariable analysis










Preoperative CA19⋅9 (units/ml) 0⋅052
≤200 135 17
>200 35 24










Tumour size (mm) 0⋅783
≤25 98 19
>25 72 17







N category <0⋅001 2⋅28 (1⋅48, 3⋅53) <0⋅001
N0 48 26
N1 122 16















Values in parentheses are 95 per cent confidence intervals. DFS, disease-free survival; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.
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Table 3 Univariable and multivariable analyses of predictors of disease-specific survival
Univariable analysis Multivariable analysis










Preoperative CA19⋅9 (units/ml) 0⋅344
≤200 135 33
>200 35 37










Tumour size (mm) 0⋅697
≤25 98 35
>25 72 33







N category <0⋅001 3⋅37 (1⋅42, 3⋅94) 0⋅001
N0 48 n.r.
N1 122 30















Values in parentheses are 95 per cent confidence intervals. DSS, disease-specific survival; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; n.r.,
not reached.
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Fig. 2 Box-and-whisker plot of Ki-67 index according to tumour
grade of differentiation. Median Ki-67 index values, interquar-
tile ranges and ranges are denoted by horizontal bars, boxes



















Follow-up was done on a regular basis by clinical evalu-
ation or telephone interview, and patients were censored
at the last available contact date.
Statistical analysis
Continuous variables are reported as median (range) val-
ues, and categorical variables as numbers with percentages.
Continuous variables were dichotomized around
the median value, except for CA19-9, for which a
cut-off value of 200 units/ml or more was previously
documented28,29 to correlate with tumour burden, spread
and early recurrence after resection of PDAC. Stu-
dent’s t test was used to compare normally distributed
continuous variables; non-parametric analyses included
Mann–Whitney U and Kruskal–Wallis tests. Survival
analysis was done with the Kaplan–Meier method and log
rank test using the following Ki-67 cut-off values: 10, 20,
30, 40, 50 and 60 per cent, tertiles and quartiles. Patients
were also stratified according to Ki-67 index and tumour
grades, and survivals were calculated accordingly.
Fig. 3 Ki-67 immunohistochemical staining in pancreatic ductal adenocarcinoma. a G1 tumour with Ki-67 index of 10 per cent or less;
b G2 tumour with Ki-67 index of 11–50 per cent; c G3 tumour with Ki-67 index above 50 per cent
a  G1 tumour, Ki-67 index ≤ 10% b  G2 tumour, Ki-67 index 11–50%
c  G3 tumour, Ki-67 index > 50%
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Fig. 4 Kaplan–Meier analysis of survival according to Ki-67 and tumour grade. a Disease-free (DFS) and b disease-specific (DSS)
survival in patients with G1 tumours and Ki-67 index of 10 per cent or less (group 1), G3 tumours and Ki-67 index above 50 per cent
(group 2), and all other patients (G1 tumours and Ki-67 index above 10 per cent, G2 tumours with any Ki-67 value and G3 tumours with










































































Multivariable analysis was performed using the Cox
regression model to evaluate significant predictors of
DFS and DSS. Significant variables in the univariable
analysis were included as co-variables; P ≤ 0⋅050 was
considered significant. Statistical analyses were performed
in SPSS® version 22.0 for Windows® (IBM, Armonk,
New York, USA).
Results
Of 272 patients who underwent resection for PDAC during
the study period, 170 met the selection criteria (Fig. S1,
supporting information).
Patient characteristics, surgical and pathological data are
presented in Table 1. PDACs were poorly differentiated
(grade G3) in 40⋅6 per cent of patients, assessed as having
T3 status in 87⋅1 per cent, with lymph node metastasis
in 71⋅8 per cent of the cohort. Lymphatic invasion was
documented in 100 per cent of the tumours with a positive
N status, but was present in only 8 per cent (4 of 48)
of N0 tumours. Some 67⋅6 per cent of tumours showed
microvascular invasion and 85⋅3 per cent had perineural
invasion. Stage IIb tumours were found in 72⋅4 per cent of
patients. The median Ki-67 index was of 30 (range 2–95)
per cent.
Survival outcomes
Median follow-up was 32 (range 0–76) months. Some
135 patients (79⋅4 per cent) had a recurrence. Median
DFS was 19 (i.q.r. 35–10) months, and median DSS
was 35 (not reached to 21) months. Ki-67 expression
of 10 and 50 per cent were the only cut-off values sig-
nificantly associated with DFS and DSS. On this basis,
survival analysis was determined using the following Ki-67
intervals: 10 per cent or less, 11–50 per cent and more
than 50 per cent. Median DFS was 24, 18 and 8 months
for these respective Ki-67 index values (P = 0⋅016) (Fig. 1a
and Table 2). Cox regression analysis showed that Ki-67
index (hazard ratio (HR) 0⋅52, 95 per cent c.i. 0⋅29
to 0⋅91; P = 0⋅022), N status (HR 2⋅28, 1⋅48 to 3⋅53;
P < 0⋅001) and resection margin status (HR 1⋅55, 1⋅06,
2⋅28; P = 0⋅024) were independent predictors of DFS
(Table 2).
DSS decreased significantly in the 10 per cent or less,
11–50 per cent and more than 50 per cent subgroups (47
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versus 33 versus 14 months respectively; P = 0⋅002) (Fig. 1b;
Table 3). Cox regression analysis identified Ki-67 index (HR
0⋅53, 95 per cent c.i. 0⋅31 to 0⋅91; P = 0⋅022), tumour grade
(HR 0⋅63, 0⋅43 to 0⋅94; P = 0⋅022), N status (HR 3⋅37, 1⋅42
to 3⋅94; P = 0⋅001) and resection margin status (HR 1⋅93,
1⋅28 to 2⋅89; P = 0⋅002) as independent predictors of DSS
(Table 3).
Stage and lymphatic invasion were not considered in
the Cox regression analysis because of the overlap with N
status.
Ki-67 and grading
Median Ki-67 was significantly higher in G3 tumours
(Fig. 2). Tumours with a Ki-67 index above 50 per cent
showed more aggressive grading: 62 per cent (13 of 21) had
a pathological grade consistent with G3, whereas none was
assessed as G1. By contrast, G3 tumours showed a more
heterogeneous Ki-67 expression (Fig. S2, supporting infor-
mation). In patients with G3 tumours, a Ki-67 index above
50 per cent was associated with significantly worse median
survival than a Ki-67 index of 50 per cent or less (DFS:
7 versus 15 months respectively, P = 0⋅035; DSS: 13 versus
29 months, P = 0⋅038). There was no association between
Ki-67 index and other pathological parameters, includ-
ing T status, N status, tumour size, vascular or perineural
invasion.
Patients were categorized into three subgroups: patients
with G1 tumours with a Ki-67 index of 10 per cent or
less (group 1); patients with G3 tumours with a Ki-67
index above 50 per cent (group 2); all other patients
(those with G1 tumours with a Ki-67 index above 10
per cent, G2 tumours with any Ki-67 index value and
G3 tumours with a Ki-67 index of 50 per cent or less)
(group 3) (Fig. 3). Patients in group 2 had poor median
survival outcomes compared with those in groups 1 and 3
(DFS: 7 months versus median survival not reached versus
19 months respectively, P < 0⋅001; DSS: 13 months versus
median survival not reached versus 35 months, P < 0⋅001)
(Fig. 4).
Discussion
Surgical resection followed by adjuvant chemother-
apy/chemoradiotherapy is considered the standard of care
for localized and resectable pancreatic cancer; however,
the majority of patients develop tumour recurrence, and up
to 30 per cent die within 1 year after surgery29–31. Early
recurrences are related to aggressive tumours, probably
associated with micrometastatic disease undetected at
operation30,31. There is therefore a need to identify more
aggressive subtypes of PDAC in order to improve their
management.
Ki-67 is a well known marker of cellular proliferation7.
Previous experience3,22 focusing on PDAC showed that
high Ki-67 expression was associated with poor patholog-
ical features, including poor tumour differentiation and
presence of lymph node metastasis.
The present study evaluated the prognostic role of Ki-67
in a series of 170 patients with PDAC and found that
patients with a Ki-67 index above 50 per cent had median
DFS and DSS approximately threefold lower than those
with a Ki-67 index of 10 per cent or less (DFS: 8 ver-
sus 24 months respectively; DSS: 14 versus 47 months).
In contrast, past reports showed no association between
Ki-67 and overall survival3,21, although Ki-67 index was
associated with the risk of recurrence within 1 year after
resection23.
In the present study a strong association between Ki-67
index and tumour grade was also found. As expected, the
combination of Ki-67 index above 50 per cent and G3
grade was associated with a greater risk of recurrence and
poor survival.
The present results may have clinical implications for
patients’ prognostic stratification. The Ki-67 index, as
an expression of a more biologically unfavourable dis-
ease, might help to discriminate which patients should
receive more aggressive adjuvant treatment. Currently,
neoadjuvant chemotherapy is recommended for patients
with anatomically borderline resectable pancreatic cancer
at increased risk of early recurrence30,32,33. Preoperative
assessment of the Ki-67 index by EUS–FNA may help to
identify patients with marginally resectable tumours based
on clinical criteria, who may benefit more from neoadju-
vant chemotherapy than upfront surgery, given the high
risk of early postoperative recurrence (those with a Ki-67
index above 50 per cent), although the feasibility of this
should be investigated further.
Limitations of this study include its retrospective design
and some issues relating to Ki-67 analysis, including
intratumoral and intertumoral heterogeneity18,21,34. In
addition, the immunohistochemistry protocol may have
involved some interobserver variability in determining
the percentage of Ki-67-positive cells12,34. To limit the
lack of uniformity and consistency in quantification,
several imaging methods have been developed to be
used in routine practice12,18. However, standardization is
needed to enable wider use of the index. Further inves-
tigations in larger cohorts are needed to validate these
results.
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